{
    "nctId": "NCT00679874",
    "briefTitle": "Assessment of Cardiotoxicity After Chemotherapy for Breast Cancer by Cardio-vascular Magnetic Resonance (MR)",
    "officialTitle": "Characterization of the Cardiotoxic Effects of Chemotherapies With Anthracyclines and Trastuzumab for Breast Cancer by Contrast-enhanced Cardiovascular Magnetic Resonance Imaging (CMR).",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 66,
    "primaryOutcomeMeasure": "Drop in ejection fraction of 10% as compared to baseline",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* First-time diagnosis of breast cancer\n* Planned chemotherapy with anthracyclines and / or Trastuzumab\n* Ability to give informed consent\n\nExclusion Criteria:\n\n* Contra-indications for CMR study (e.g. implanted pacemaker / ICD; severe renal impairment (GFR\\< 35 ml/min); severe claustrophobia)\n* Previous history of non-ischemic cardiomyopathies or myocardial inflammation\n* Inability to give informed consent\n* Concomitant drug abuse (e.g. cocaine)\n* Expected life expectancy \\< 6 months",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}